Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.43M | 11.85M | 11.49M | 11.11M | 13.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 800.00 | 800.00 | 800.00 | 800.00 | 0.00 |
| Total Operating Expenses | 45.64M | 35.80M | 30.19M | 23.61M | 22.13M |
| Operating Income | -45.64M | -35.80M | -30.19M | -23.61M | -22.13M |
| Income Before Tax | -42.37M | -32.64M | -26.56M | -21.23M | -42.28M |
| Income Tax Expenses | 5.40K | 10.10K | 10.10K | 10.10K | 10.10K |
| Earnings from Continuing Operations | -42.37 | -32.65 | -26.57 | -21.24 | -42.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.37M | -32.65M | -26.57M | -21.24M | -42.29M |
| EBIT | -45.64M | -35.80M | -30.19M | -23.61M | -22.13M |
| EBITDA | -45.03M | -35.35M | -29.89M | -23.46M | -22.02M |
| EPS Basic | -1.07 | -0.83 | -0.73 | -0.84 | -3.91 |
| Normalized Basic EPS | -0.68 | -0.52 | -0.49 | -0.57 | -0.80 |
| EPS Diluted | -1.07 | -0.83 | -0.73 | -0.84 | -3.91 |
| Normalized Diluted EPS | -0.68 | -0.52 | -0.49 | -0.57 | -0.80 |
| Average Basic Shares Outstanding | 158.10M | 157.11M | 145.46M | 117.89M | 86.95M |
| Average Diluted Shares Outstanding | 158.10M | 157.11M | 145.46M | 117.89M | 86.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |